#### ![calendar-Icon](/themes/custom/cosmos/patterns/images/calendar-v2.svg)January 31, 2025

 

 #### Basel, Switzerland

 

 

 Novartis announces the company’s fourth quarter and 2024 full year financial results. 

 

 [    Media release  (428 KB)   ](https://www.novartis.com/sites/novartis_com/files/q4-2024-media-release-en.pdf) [    Medienmitteilung  (442 KB)   ](https://www.novartis.com/sites/novartis_com/files/q4-2024-media-release-de.pdf) 

 



 [    Condensed financial report  (520 KB)   ](https://www.novartis.com/sites/novartis_com/files/2025-01-interim-financial-report-en.pdf) 

 



---

## Webcast and presentation

[Watch the webcast](https://edge.media-server.com/mmc/p/7vboajm5/)  
14:00 CET | 13:00 GMT | 08:00 EST

[Download the podcast (MP3 30 MB)](https://prod1.novartis.com/sites/novartis_com/files/2025-02/q4-2024-investor-presentation.mp3)  
[Read the transcript](/investors/financial-data/quarterly-results/2024-q4-and-full-year-results-transcript "2024 Q4 and full year results presentation and transcript")



[Download the investor presentation (PDF 4.7 MB)](/sites/novartis_com/files/q4-2024-investor-presentation.pdf "q4-2024-investor-presentation.pdf")

[Novartis Q4 2024 impact and sustainability update (PDF 1.0 MB)](https://prod1.novartis.com/sites/novartis_com/files/novartis-q4-2024-impact-and-sustainability-update.pdf)







---



 



 ![Kate Kostelyk, IgA nephropathy (IgAN) patient, and her labrador Dakoda in Mims, Florida](/sites/novartis_com/files/styles/cta_image/public/2025-01/portrait-of-kate-kostelyk-and-her-labrador.jpg.webp?itok=4HIqaVLd "Kate Kostelyk, IgA nephropathy (IgAN) patient, and her labrador Dakoda in Mims, Florida") 

 

##  Novartis in Society Integrated Report 2024 

The Novartis in Society Integrated Report provides an overview our business, strategy and performance, and describes how we create sustainable value for stakeholders and society.

[English (PDF 5.0 MB)](/sites/novartis_com/files/novartis-integrated-report-2024.pdf)



 

 



 





 ![Prof. Dr. Ulf Landmesser (center) at the Charité hospital in Berlin, Germany](/sites/novartis_com/files/styles/cta_image/public/2025-01/prof-dr-ulf-landmesser-at-charite-hospital-berlin-germany.jpg.webp?itok=Eloyyei7 "Prof. Dr. Ulf Landmesser (center) at the Charité hospital in Berlin, Germany") 

 

##  Annual Report 2024 and US Securities & Exchange Commission Form 20-F 2024 

These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices. They are filed with the SIX Swiss Exchange in Switzerland and the Securities and Exchange Commission in the US.

[Annual Report 2024 (PDF 3.5 MB)](/sites/novartis_com/files/novartis-annual-report-2024.pdf) | [Form 20-F 2024 (PDF 3.4 MB)](/sites/novartis_com/files/novartis-20-f-2024.pdf "novartis-20-f-2024.pdf")



 

 



 





 [ 

 

###  Novartis Pipeline 

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines.

 

 

 ](https://www.novartis.com/research-development/novartis-pipeline) [ 

 

###  Executive Committee of Novartis (ECN) biographies 

Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the business operations of Group companies.

 

 

 ](/about/executive-committee) 





 

 [Download the Novartis Pipeline from the 2024 Annual Report (PDF 0.1 MB)](/sites/novartis_com/files/novartis-pipeline-2024-annual-report.pdf "Download the Novartis Pipeline from the 2024 Annual Report (PDF 0.1 MB)") 

 




.events-page-tags .field--name-field-event-tags {
    display: none;
}